A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS

Summary

This study is being done to evaluate the safety and effectiveness of APTO-253 for the treatment of patients with the condition of acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) for which either the standard treatment has failed, is no longer effective, or can no longer be administered safely or poses a risk for your general well being.

Timeline

Start

2014-10

Primary completion

2021-09

Completion

2021-09

Outcome

Outcome not reported

Stopped: “Drug manufacturing process and procedure review”

Drugs

Indications